Oxiracetam

DB13601

small molecule experimental

Deskripsi

Struktur Molekul 2D

Berat 158.157
Wujud -

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

663 Data
Buprenorphine Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxiracetam.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxiracetam.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Oxiracetam.
Hydrocodone Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxiracetam.
Magnesium sulfate The therapeutic efficacy of Oxiracetam can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Oxiracetam may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxiracetam.
Mirtazapine Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Oxiracetam.
Orphenadrine Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Oxiracetam.
Pramipexole Oxiracetam may increase the sedative activities of Pramipexole.
Ropinirole Oxiracetam may increase the sedative activities of Ropinirole.
Rotigotine Oxiracetam may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Oxiracetam.
Sodium oxybate Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxiracetam.
Thalidomide Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Oxiracetam.
Ethanol Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxiracetam.
Zimelidine The risk or severity of adverse effects can be increased when Oxiracetam is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Oxiracetam is combined with Dapoxetine.
Seproxetine The risk or severity of adverse effects can be increased when Oxiracetam is combined with Seproxetine.
Fluvoxamine The risk or severity of adverse effects can be increased when Oxiracetam is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Oxiracetam is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Oxiracetam is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Oxiracetam is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Oxiracetam is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Oxiracetam is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Oxiracetam is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Oxiracetam is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Oxiracetam is combined with Escitalopram.
Milnacipran The risk or severity of adverse effects can be increased when Oxiracetam is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Oxiracetam is combined with Desvenlafaxine.
Levomilnacipran The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Oxiracetam.
Indalpine The risk or severity of adverse effects can be increased when Oxiracetam is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Oxiracetam is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Oxiracetam is combined with Alaproclate.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Oxiracetam.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Oxiracetam.
Zopiclone The risk or severity of adverse effects can be increased when Oxiracetam is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Oxiracetam.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Oxiracetam.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Oxiracetam.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Oxiracetam.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Oxiracetam.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Oxiracetam.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Oxiracetam.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Oxiracetam.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Oxiracetam.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Oxiracetam.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Oxiracetam.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Oxiracetam.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Oxiracetam.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Oxiracetam.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Oxiracetam.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Oxiracetam.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Oxiracetam.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Oxiracetam.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Oxiracetam.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Oxiracetam.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Oxiracetam.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Oxiracetam.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Oxiracetam.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Oxiracetam.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Oxiracetam.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Oxiracetam.
Thiethylperazine The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Oxiracetam.
Palonosetron The risk or severity of CNS depression can be increased when Palonosetron is combined with Oxiracetam.
Dexbrompheniramine The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Oxiracetam.
Metocurine iodide The risk or severity of CNS depression can be increased when Metocurine iodide is combined with Oxiracetam.
Secobarbital The risk or severity of CNS depression can be increased when Secobarbital is combined with Oxiracetam.
Methocarbamol The risk or severity of CNS depression can be increased when Methocarbamol is combined with Oxiracetam.
Triprolidine The risk or severity of CNS depression can be increased when Triprolidine is combined with Oxiracetam.
Meperidine The risk or severity of CNS depression can be increased when Meperidine is combined with Oxiracetam.
Metharbital The risk or severity of CNS depression can be increased when Metharbital is combined with Oxiracetam.
Quinine The risk or severity of CNS depression can be increased when Quinine is combined with Oxiracetam.
Methohexital The risk or severity of CNS depression can be increased when Methohexital is combined with Oxiracetam.
Gallamine triethiodide The risk or severity of CNS depression can be increased when Gallamine triethiodide is combined with Oxiracetam.
Entacapone The risk or severity of CNS depression can be increased when Entacapone is combined with Oxiracetam.
Oxycodone The risk or severity of CNS depression can be increased when Oxycodone is combined with Oxiracetam.
Dextromethorphan The risk or severity of CNS depression can be increased when Dextromethorphan is combined with Oxiracetam.
Mephenytoin The risk or severity of CNS depression can be increased when Mephenytoin is combined with Oxiracetam.
Cisatracurium The risk or severity of CNS depression can be increased when Cisatracurium is combined with Oxiracetam.
Fenfluramine The risk or severity of CNS depression can be increased when Fenfluramine is combined with Oxiracetam.
Mazindol The risk or severity of CNS depression can be increased when Mazindol is combined with Oxiracetam.
Fluticasone propionate The risk or severity of CNS depression can be increased when Fluticasone propionate is combined with Oxiracetam.
Lisuride The risk or severity of CNS depression can be increased when Lisuride is combined with Oxiracetam.
Ethosuximide The risk or severity of CNS depression can be increased when Ethosuximide is combined with Oxiracetam.
Thiopental The risk or severity of CNS depression can be increased when Thiopental is combined with Oxiracetam.
Cisapride The risk or severity of CNS depression can be increased when Cisapride is combined with Oxiracetam.
Butorphanol The risk or severity of CNS depression can be increased when Butorphanol is combined with Oxiracetam.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul